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Abstract
Background—Cilengitide is a selective integrin inhibitor that is well tolerated and has
demonstrated biological activity in patients with recurrent malignant glioma. The primary
objectives of this randomized phase II trial were to determine safety and efficacy of cilengitide
when combined with radiation and temozolomide for newly diagnosed glioblastoma (GBM) and
to select a dose for comparative clinical testing.
Methods—A total of 112 patients were accrued. Eighteen patients received standard RT+TMZ
with cilengitide in a safety run-in phase followed by a randomized phase II with ninety-four
patients assigned to either 500 or 2000 mg dose groups. The trial was designed to estimate overall
survival benefit when compared with the NABTT internal historical control or the published
EORTC 26981 data.
Results—Cilengitide at all doses studied was well tolerated with radiation and temozolomide.
The median survival was 19.7 months for all patients, 17.4 months for those receiving the 500 mg
dose, 20.8 months for those receiving the 2000mg dose, 30 months for patients with methylated
MGMT promoters and 17.4 months for unmethylated patients. For patients ages 70 and younger,
the median survival and survival at 24 months was superior to that observed in the EORTC trial
(20.7 months vs 14.6 months and 41% vs 27% (p=0.008) respectively).
Conclusions—Cilengitide is well tolerated when combined with standard chemoradiation and
may improve survival for patients newly diagnosed with GBM regardless of MGMT status. From
an efficacy and safety standpoint, future trials of this agent in this population should utilize the
2000 mg dose.
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Cilengitide (EMD121974, cyclo-L-Arg-Gly-L-Asp-D-Phe-N (Me) L-Val, Merck KGaA,
Darmstadt, Germany) is a cyclic RGD containing peptide that binds to αvβ3 and αvβ5 with
nanomolar affinity (1). In cell-based assays, cilengitide inhibited both αvβ3 and αvβ5
mediated function with IC50 values in the low micromolar range and inhibited angiogenesis
in in vitro model systems (2, 3). Preclinical animal studies of glioma in both mice and rat
models demonstrated tumor control and survival advantages (4-7).
The experience of cilengitide in patients with glioma has also demonstrated biological
activity as measured by responses, progression-free survival, and overall survival. The initial
phase I study in recurrent malignant glioma by Nabors et al failed to define a maximum
tolerated dose (MTD) but suggested higher doses to be more active by measuring
improvements in tumor blood flow with perfusion MRI (8). A randomized phase II trial in
recurrent disease evaluated low and high dosees of the drug and likewise suggest greater
biological activity at the higher dose (2000 mg twice a week) (9). In newly diagnosed
patients with GBM, cilengitide at 500 mg twice a week was combined with standard
therapy, temozolomide and radiation (10). When compared to historical controls, the authors
noted improvements in both progression free survival and overall survival that appeared to
be enhanced in the MGMT methylated patient population.
The rationale for the study of integrin antagonists in the setting of primary brain
malignancies is thus provided. The present study was undertaken to determine the toxicities
of cilengitide in patients with newly diagnosed GBM and determine the overall survival for
patients treated with different doses of the agent.
PATIENTS AND METHODS
Eligibility Criteria
This study was sponsored by the Cancer Therapy Evaluation Program at the National Cancer
Institute and conducted by the New Approaches to Brain Tumor Therapy CNS Consortium
(www.nabtt.org for participating institutions). The protocol was reviewed and approved by
the Institutional Review Board at each participating institution and all patients signed
informed consent.
Patients eligible for enrollment met the following criteria: ≥18 years of age, newly
diagnosed and histologically proven glioblastoma, maintained on a stable dose of
corticosteriods for ≥5 days, recovered from previous surgery, Karnofsky performance status
of ≥60%, adequate hematologic, renal, and hepatic function, agree to practice acceptable
birth control method, a mini mental status exam score of ≥15, and capable of providing
informed consent.
Treatment Plan
This study was designed as an open-label, randomized phase II study to evaluate the safety
and efficacy of cilengitide in terms of overall survival. In addition, it was designed to pick
one of two cilengitide doses in combination with standard RT+TMZ to be used in future
clinical trials in this patient population. The phase II study was preceded by a safety run-in
combining cilengitide with standard chemoradiation for patients newly diagnosed with
glioblastoma. A total of 3 predefined doses (500, 1000, and 2000 mg twice a week) were
selected. The study drug was infused intravenously over a one hour period on a twice a week
schedule with a minimum of 72 hours between infusions for 4 weeks. This four week
interval was considered a treatment cycle. The starting dose and schedule were selected
based on previous studies of cilengitide in malignant glioma (8, 9). Toxicity was evaluated
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according to the National Cancer Institute Common Toxicity Criteria version 3.
Temozolomide was administered daily at 75 mg/M2 concurrent with radiation therapy
followed by a maintenance phase of 150-200 mg/M2 for 5 consecutive days out of every 28
day time interval. Radiation therapy was conventional treatment as utilized by the Radiation
Therapy Oncology Group (RTOG). This consisted of treatment to the tumor plus a generous
margin for a total dose of 6000 cGy in 30 fractions. During the randomized phase II portion,
patients were randomized into one of two treatment groups (500 mg or 2000 mg) using a
stratified and randomly permuted blocks method. The stratification was based on common
prognostic factors of the disease to include age (≤50 or >50 years), KPS (≤80 or >80), and
tumor status (measurable or unmeasurable disease). Patients were treated with adjuvant
temozolomide for six months and with cilengitide until there was disease progression,
unacceptable toxicity, or voluntary withdrawal.
Study Requirements
Tumor tissue from the patient’s surgery at diagnosis was collected for MGMT methylation
status determination. Patients underwent evaluation of measurable disease by cranial
magnetic resonance (MR) imaging four weeks after the complete of cilengitide plus
chemoradiation and then after eight weeks thereafter. Laboratory studies including a
chemistry profile and liver function enzymes were determined at baseline and prior to each
odd numbered maintenance cycle. Complete blood counts were determined at baseline,
weekly during radiation therapy, and monthly during maintenance. A urinalysis, EKG, and
chest XRAY were completed at baseline.
MGMT Promoter Methylation Testing
Patient samples were tested for MGMT promoter methylation status using previously
described procedures (11) by MDxHealth (Liege, Belgium). Briefly, forty microns of a
formalin-fixed, paraffin embedded (FFPE) tumor sample were deparaffinated, digested and
the genomic DNA isolated by the standard phenol-chloroform method. Up to 1,500 ng of
gDNA was then treated by sodium bisulfite resulting in the deamination of non-methylated
cytosine bases to uracil bases. Quantitative PCR for the methylated version of the MGMT
gene and for the beta-Actin gene was then performed on the sample. The beta-Actin gene
was used to establish sample quality and also used to normalize the test output. A threshold
of 1,250 copies of actin (ACTB) was necessary in order to properly interpret the sample.
The normalized ratio of mMGMT copy number to ACTB copy number was then calculated
(mMGMT/ACTB × 1000). Samples with mMGMT:ACTB ratio of 2 or greater were
considered methylated below this, the samples were considered unmethylated.
Statistical Considerations
The trial was designed to accrue 94 patients and analysis required 63 deaths. This would
provide 94% power to detect a 30% or larger reduction in hazard of death (the hazard rate)
compared to the NABTT internal historical control at an alpha level of 0.1. Comparison with
the EORTC data was also proposed. Survival time was calculated from histological
diagnosis until death from any cause, and surviving patients were censored at the time of last
follow-up. The trial also was designed to further evaluate the safety and to identify either the
500 mg or the 2000mg dose as being the best for future clinical trials in this setting. This
trial design was chosen as a consequence of our previous NABTT phase I study of this agent
which suggested that the toxicities at the two dose levels woul be similar and that activity
was seen across the range of doses tested (8) The overall hazard rate of death was defined as
number of death per person-year of follow-up. A decision rule was included in the trial
desgn specifying that a ≥30% reduction in the hazard rate compared to the NABTT internal
historical control (which did not include temozolomide treated patients) would provide
strong evidence to proceed to a formal comparative trial.
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Patient characteristics and toxicities were summarized using appropriate descriptive
statistics. Chi-Square statistic was used for proportion comparison. Student-T test was used
for comparison of continuous data.
The method of Kaplan and Meier (12) was used to estimate overall survival. Confidence
intervals were calculated using standard methods. Cox proportional-hazards regression
model was used to estimate the hazard ratio for death attributable to the treatment and to
prognostic factors. To pick a more efficacious dose in term of overall survival advantage,
the two doses was compared using a non-parametric Log-Rank test.
All p-values are reported as two-sided and all analyses were performed using SAS version
9.1.3 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Between April 2005 and December 2007, 112 patients were enrolled into the study. Their
characteristics are described in Table 1. All patients had prior surgery and were
histologically diagnosed with glioblastoma. The patient characteristics and prognostic
factors were well balanced between treatment groups and comparable to historical controls.
At the time of data cut-off (May 30, 2010), 6 patients were continuing to receive study drug
infusions.
Toxicity
Patient infusion with cilengitide did not produce any acute toxicities. During the safety run-
in portion of the study, there were no DLTs at any dose level which were sufficient to define
a MTD. During the randomized phase, hematologic and non-hematologic grade 3 or 4
adverse events were relatively evenly distributed with 48 occuring in the 500 mg cohort and
35 in the 2000 mg cohort. Hematological toxicities comprised 58% of the adverse events in
patients receiving the 500 mg dose and 34% in the 2000 mg dose. These adverse events
were uniformly attributed to the radiation and temozolomide. The non-hematological
toxicities were also fairly evenly spread across the dose groups and exhibited no consistent
concerning toxicity profiles. The range of adverse events seen is presented in Table 2.
Response Assessment
Overall survival—The estimated median survival time for all 112 patients enrolled on this
study was 19.7 months (95% Confidence Interval (CI): 16.6 -21.9.months). The overall
hazard rate of death was 0.494 (95% CI: 0.4 -0.6) per person-year of follow-up (Figure 1)
and the estimated 2 year overall survival (OS) rate was 38% (95% CI: 29-48%). No patients
were lost to follow-up.
In comparison to the NABTT historical control goup, which did not include patients treated
with temozolomide, the unadjusted hazard ratio of death is 0.41 (95%CI: 0.32-0.53;
p=0.0001) which constitutes a 59% reduction in the hazard of death. After adjusting for
known prognostic factors (age (p=0.0003), KPS (p=0.004), and surgical procedure
(p=0.003)), the adjusted hazard ratio of death is 0.39 (95%CI: 0.3-0.5, p<0.0001). In this
trial, there were 101 patients age ≤70. Their median survival was 20.7 months (95%CI:
17.2-24.0) which is higher that the similarly aged patients in the EORTC study where the
same radiation and temozolomide were used and the median survival was 14.6 months
(95%CI: 13.2-16.8). The 24-month survival rate with cilengitide was 41% (95%CI: 31-51)
as compared to the EORTC results of 27% (p=0.008, 95%CI: 21-32%).
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In the randomized portion of the trial for dose selection, ninety-four patients were assigned
into either the 500 mg (46 pts) or the 2000 mg (48 pts) dose groups. An estimated median
OS for the 500 mg group was 17.4 months (95% CI: 13.3-21.6 months) compared to a
median OS of 20.8 months in the 2000 mg dose group (Figure 2). The unadjusted hazard
ratio of death was 0.83 (95%CI: 0.5-1.3; p=0.4), a 17% reduction in the hazard of death for
patient treated in the 2000 mg dose group compared to patients in the 500 mg dose group.
After adjusting for stratification factors and well-known prognostic factors such as age,
KPS, surgical procedure, and MGMT status at baseline, the adjusted hazard ratio of death
was 0.8 (95%CI: 0.5-1.28), a 20% reduction in hazard of death for patient treated in the
2000 mg dose group compared to patients in the 500 mg dose group. The two years survival
rates among those randomized patients are 28% (95%CI: 16-44%) and 44% (95%CI:
30-59%) for the 500 mg dose and the 2000 mg dose group, respectively.
Progression-free survival (PFS): PFS was not a primary objective of this trial. However,
disease progression was recorded in patient follow-up form as an off treatment criteria. The
PFS was calculated from the date of diagnosis to the date of disease progression. A total of
103 (92%) out 112 patients had progressive disease or had died by the data cut-off date. The
median progression-free survival was 9.97 months (95% CI: 8.3-11.1 months) for all adult
patients and 10.6 months (95%CI: 8.5-13.2 months) for patients aged from 18 to 70. Among
the 94 randomized patients, the PFS were similar between the two doses. The median PFS
was 9.5 months (95%CI: 6.9-12.2 months) and 9.3 month (95% CI: 7.7-11.1months) for the
500mg group and the 2000mg group respectively. After adjusting for age, KPS, surgical
procedure, and MGMT status at baseline, the adjusted hazard ratio of PFS is 1.07 (95%CI:
0.67-1.68) for patients in the 2000 mg group versus the 500 mg group.
MGMT status: A total of 88 patients (79%, 88/112) had tumor tissue collected from
baseline. Following neuropathological review, 79 were felt to have adequate tissue for
baseline MGMT assessment. Twenty-one patients (19%) out of 112 had MGMT
methylation at baseline, 48 (43%) unmethylated, and 43 (38%) methylation status unknown,
hence, a MGMT methylation frequency of evaluable cases of 30% (21/69). The methylation
status unknown includes those tested but judged invalid due to insufficient number of beta-
actin gene copies or tumor tissue was not collected or available. The overall survival
stratified by MGMT status at the baseline alone for all 112 patients is shown in Figure 3.
The estimated median OS of patients who were methylated, unmethylated and unknown 30
months (95% CI: 16.6-35.4 months), 19.1 months (95% CI: 14.6-21.9 months), and 17.4
months (95% CI: 13.7-24.2 months), respectively.
DISCUSSION
In this report, we extend our previous studies with the integrin antagonist, cilengitide to the
newly diagnosed glioblastoma population and augment the safety and toxicity description of
the compound with standard radiation and chemotherapy. Overall cilengitide was well
tolerated without new or unexpected toxicities in this patient population when combined
with radiation and temozolomide. The majority of the adverse events noted in the trial are
consistent with the expected toxicities of standard chemoradiation. Specific events that may
be induced or attributed by an agent with anti-angiogenic or anti-invasive properties such as
hemorrhage were not noted. These findings are consistent with other studies of cilengitide
for newly diagnosed GBM (10).
The primary endpoint of this study was to evaluate overall survival in patients newly
diagnosed with GBM treated with cilengitide in conjunction with standard chemoradiation
and to select a dose for comparative clinical trial testing. The trial achieved a 61% reduction
in the hazard rate of death compared to NABTT historical control, which exceeded the
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protocol decision rule of a 30% or greater reduction in the failure rate. As the NABTT
historical database did not include the use of temozolomide administered with and following
radiation, the analysis planned before the 2005 publication of the EORTC results is of
marginal importance in the current therapeutic environment. However, the observed median
OS for all 112 patients enrolled in the trial was 19.7 months which compare very favorably
with the 16.1 months reported from a recent study of low dose cilengitide (500 mg) in the
same setting(10) and with the 14.6 months noted in the EORTC phase III trial (13) which
included a better prognostic group of only patients age 70 or less. In addition, the celingitide
treated patients had an improved two year survival for similarly aged patients (41% vs 27%).
Secondary objectives were to examine toxicity and survival in patients treated with low (500
mg) and high doses (2000 mg) of cilengitide and to choose the dose that should be studied in
future phase III trials. The toxicities were similar. However, overall survival demonstrates a
median OS of 20.8 months for the 2000 mg group and 17.4 months for the 500 mg group
(adjusted hazard ratio of death is 0.8) and 2-year survival rates, of 44% in the 2000 mg
group and 28% in the 500 mg group. Although these differences are not statistically
different using a Cox Regression model (data not shown), this trial was not intended or
powered to conduct such a comparison as our goal was to simply select the best dose to use
in future studies. This data strongly suggest that Cilengitide dosed at 2000 mg twice a week
with standard radiation and chemotherapy is the superior choice for phase III trials in
patients with newly diagnosed GBM.
The determination of MGMT status in GBM has been shown to predict survival (14). We
were able to determine MGMT status in 62% of the patients on study with 21 (30%)
methylated of 69 with valid test results. In figure 3, Kaplan-Meier survival curves illustrate
improved survival for MGMT methylated patients relative to unmethylated and unknowns.
This observation is in keeping with other studies. It was not possible to make a reasonable
analysis of the effect MGMT status had on survival based on the dose of cilengitide due to
the small number. It does appear cilengitide impacted survival for the unmethylated as well
as the methylated patients. We observed a median OS of 30 months for methylated and 19.1
months for unmethylated patients. This would be an improvement for both genotypes
compared to EORTC 26981 where methylated patients treated with TMZ+RT had a median
OS of 21.7 months and unmethylated 12.7.
The use of an integrin antagonist in the treatment of malignant glioma is emerging as a
strong complement to radiation and temozolomide in patients with newly diagnosed GBM.
The ability to exploit the novel integrin mediated signaling cascade brings to bear a new
class of compounds for this disease. The randomized nature of the current study provides
strong support for the use of 2000 mg dose and lays a foundation for the current comparative
trials ongoing with cilengitide (CENTRIC). In addition, the different mechanism of action
and excellent tolerability may permit cilengitide to also be combined with anti-VEGF agents
for newly diagnosed GBM (15).
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Kaplan-Meier survival curve. Kaplan-Meier survival curve for overall survival and 95% CI
(shared area) for patients age ≤ 70 treated with RT+TMZ+EMD, the same age range as in
the EORTC phase III trial. The black circle with 95% CI represents the mOS of 14.6 months
for the EORTC phase III trial. The dash line represents the NABTT internal historical
control prior TMZ.
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Kaplan-Meier overall survival curves for patients treated in the randomized phase II
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Kaplan-Meier plots of the overall survival curves stratified by patient’s MGMT status at the
baseline
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RT+TMZ +EMD 500mg RT+TMZ +EMD 2000mg NABTT Historical RT+Chemo
Characteristics N=112 N=46 N=48 N=235
Age – year
 Median 55.5 56.3 54.9 55
 Range 22--88 35—88 22--81 21--82
Sex – no .(%)
 Male 66 (59) 28 (61) 29 (60) 151 (64)
 Female 46 (41) 18 (39) 19 (40) 84 (36)
Karnofsky Performance
Status no. (%)
 100 27 (24) 8 (17) 15 (31) 33 (18)
 90 51 (46) 27 (59) 18 (38) 93 (50)
 80 15 (13) 3 (7) 7 (15) 31 (17)
 70 15 (13) 6 (13) 6 (13) 21 (11)
 60 4 (4) 2 (4) 2 (4) 7 (4)
Surgical Procedure no.
(%)
 Biopsy 25 (22) 10 (22) 9 (19) 29 (16)
 Craniotomy 86 (77) 35 (76) 39 (81) 156 (84)
 Other 1 (1) 1 (2)
Corticosteroid Therapy -
no. (%)
 Yes 82 (74) 33 (72) 36 (77) 157 (67)
 No 28 (24) 13 (28) 11 (23) 24 (10)




 Glioblastoma 112 (100) 46 (100) 48 (100) 181 (98)
 Other 3 (2)
MGMT no. (%)
 Methylated 21 (19) 11 (24) 7 (15)
 Unmethylated 48 (43) 21 (46) 18 (37)
 Unknown 43 (38) 14 (30) 23 (48)
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Nonhematological Grade 3 or 4 Adverse Events (n= number of pts)
Toxicity Grade 3-4 500mg 1000mg 2000mg Total














SGPT 1 1 2
Somnolence 1 1
Thrombosis 3 3
Vomiting 1 1 2
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Table 3
Comparison of baseline and overall survival for all subjects, those age 18-70 only, in RT+TMZ+EMD to
EORTC phase III cohort
Trial RT+TMZ+EMD EORTC Phase III
Age 18-70 (n=101) Age 18-70 (n=287)
No. of patients (%) No. of patients (%)
Baseline:
Age Median (range), yr 55 (23-70) 56 (19-70)
KPS, 90-100 72 (71) 249 (86)
Surgery, Debulking 77 (76) 239 (83)
Corticosteroids, yes 75 (76) 193 (67)
Histology, GBM 101 (100) 221 (92)
Outcome:
Median overall survival (95% CI) 20.7 (17-24) 14.6 (13-17)
% overall survival at 24 months (95% CI)* 41 (31 -51) 27 (21-32)
*p< 0.05
Cancer. Author manuscript; available in PMC 2013 November 15.
